Brief: Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Can Fite Biopharma

30/01/2024 12:07

Jan 30 (Reuters) - Can Fite Biopharma Ltd  CANF.TA :
    * CAN-FITE EXPANDS THE OUT-LICENSING DEAL WITH EWOPHARMA TO
INCLUDE THE PANCREATIC CANCER INDICATION
    * CAN FITE BIOPHARMA LTD - EXPANDED ITS OUT LICENSING
TRANSACTION
WITH EWOPHARMA AG
    * CAN FITE BIOPHARMA LTD -UNDER TERMS OF DISTRIBUTION
AGREEMENT,
EWOPHARMA AG PAID CAN-FITE AN UPFRONT PAYMENT OF US$2.25 MILLION
    * CAN FITE BIOPHARMA-EWOPHARMA AG RECEIVED EXCLUSIVE RIGHT
TO
MARKET, SELL PICLIDENOSON IN CENTRAL EASTERN EUROPEAN COUNTRIES
    * CAN FITE BIOPHARMA LTD - EWOPHARMA AG RECEIVED EXCLUSIVE
RIGHT
TO MARKET AND SELL NAMODENOSON IN CEE COUNTRIES AND SWITZERLAND

Source text for Eikon:  ID:nBwbSF7mKa 
Further company coverage:  CANF.TA 

 ((Reuters.Briefs@thomsonreuters.com;))